Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma.
We are thrilled to announce the publication of our paper, entitled “TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity,” in the prestigious journal Haematologica. This study represents a collaborative effort between T-E Meds and Far Eastern Memorial Hospital, jointly exploring new breakthroughs and clinical potential of TE-1146 in medical applications.
Link to article: